IF 5.6 2区医学

mAbs Pub Date : 2025-12-01 Epub Date: 2025-01-24 DOI: 10.1080/19420862.2025.2451296

Brett Robison, S J Diong, Anusha Kumar, Thomas M Moon, Olin Chang, Bryant Chau, Christine Bee, Ishita Barman, Arvind Rajpal, Alan J Korman, Sean West, Pavel Strop, Peter S Lee

{"title":"Engineered ipilimumab variants that bind human and mouse CTLA-4.","authors":"Brett Robison, S J Diong, Anusha Kumar, Thomas M Moon, Olin Chang, Bryant Chau, Christine Bee, Ishita Barman, Arvind Rajpal, Alan J Korman, Sean West, Pavel Strop, Peter S Lee","doi":"10.1080/19420862.2025.2451296","DOIUrl":"10.1080/19420862.2025.2451296","url":null,"abstract":"Testing of candidate monoclonal antibody therapeutics in preclinical models is an essential step in drug development. Identification of antibody therapeutic candidates that bind their human targets and cross-react to mouse orthologs is often challenging, especially for targets with low sequence homology. In such cases, surrogate antibodies that bind mouse orthologs must be used. The antibody 9D9, which binds mouse CTLA-4, is a commonly used surrogate for CTLA-4 checkpoint blockade studies in mouse cancer models. In this work, we reveal that 9D9 has significant biophysical dissimilarities to therapeutic CTLA-4 antibodies. The 9D9-mCTLA4 complex crystal structure was determined and shows that the surrogate antibody binds an epitope distinct from ipilimumab and tremelimumab. In addition, while ipilimumab has pH-independent binding to hCTLA-4, 9D9 loses binding to mCTLA-4 at physiologically relevant acidic pH ranges. We used phage and yeast display to engineer ipilimumab to bind mouse CTLA-4 with single-digit nM affinity from an initial state with no apparent binding. The engineered variants showed pH-independent and cross-reactive binding to both mouse and human CTLA-4. Crystal structures of a variant in complex with both mouse and human CTLA-4 confirmed that it targets an equivalent epitope as ipilimumab. These cross-reactive ipilimumab variants may facilitate improved translatability and future mechanism-of-action studies for anti-CTLA-4 targeting in murine models.","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"17 1","pages":"2451296"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases. 强效人源化TNFα抑制纳米体在TNFα介导疾病治疗中的应用

IF 5.6 2区医学

mAbs Pub Date : 2025-12-01 Epub Date: 2025-05-14 DOI: 10.1080/19420862.2025.2498164

Tao Yin, Aubin Ramon, Matthew Greenig, Pietro Sormanni, Luciano D'Adamio

{"title":"Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases.","authors":"Tao Yin, Aubin Ramon, Matthew Greenig, Pietro Sormanni, Luciano D'Adamio","doi":"10.1080/19420862.2025.2498164","DOIUrl":"https://doi.org/10.1080/19420862.2025.2498164","url":null,"abstract":"Tumor necrosis factor-alpha (TNFα) is a key pro-inflammatory cytokine implicated in the pathogenesis of numerous inflammatory and autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, and neurodegenerative disorders such as Alzheimer's disease. Effective inhibition of TNFα is essential for mitigating disease progression and improving patient outcomes. In this study, we present the development and comprehensive characterization of potent humanized TNFα inhibitory nanobodies (TNFI-Nbs) derived from camelid single-domain antibodies. In silico analysis of the original camelid nanobodies revealed low immunogenicity, which was further reduced through machine learning-guided humanization and developability optimization. The two humanized TNFI-Nb variants we developed demonstrated high anti-TNFα activity, achieving IC₅₀ values in the picomolar range. Binding assays confirmed their high affinity for TNFα, underscoring robust neutralization capabilities. These TNFI-Nbs present valid alternatives to conventional monoclonal antibodies currently used in human therapy, offering potential advantages in potency, specificity, and reduced immunogenicity. Our findings establish a solid foundation for further preclinical development and clinical translation of TNFα-targeted nanobody therapies in TNFα-mediated diseases.","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"17 1","pages":"2498164"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12080732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The physiological limits of bispecific monoclonal antibody tissue targeting specificity. 双特异性单克隆抗体组织靶向特异性的生理极限。

IF 5.6 2区医学

mAbs Pub Date : 2025-12-01 Epub Date: 2025-04-13 DOI: 10.1080/19420862.2025.2492236

Armin Sepp, Felix Stader, Abdallah Derbalah, Cong Liu, Adriana Zyla, Iain Gardner, Masoud Jamei

{"title":"The physiological limits of bispecific monoclonal antibody tissue targeting specificity.","authors":"Armin Sepp, Felix Stader, Abdallah Derbalah, Cong Liu, Adriana Zyla, Iain Gardner, Masoud Jamei","doi":"10.1080/19420862.2025.2492236","DOIUrl":"https://doi.org/10.1080/19420862.2025.2492236","url":null,"abstract":"Bispecific monoclonal antibodies (bsmAbs) are expected to provide targeted drug delivery that overcomes the dose-limiting toxicities often accompanying antibody-drug conjugates (ADC) in clinical practice. Much attention has been paid in the past to target selection, mAb affinities and the payload linker design, but challenges remain. Here, we demonstrate, by physiologically based pharmacokinetic (PBPK) in silico modeling and simulation, that the tissue-targeting accuracy of mono- and bispecific antibody therapeutics is substantially limited by normal physiological characteristics like organ volumes, blood flow rates, lymphatic circulation, and rates of extravasation. Only a small fraction of blood flows through solid tumor, where the diffusion-driven extravasation is relatively slow compared with many other organs. EGFR and HER2 are used as model antigens based on their experimentally measured tissue and tumor expression levels, but the approach is generic and can account for the cellular expression variation of targets. The model confirms experimental observations that only about 0.1-1% of the dosed mAb is likely to reach the tumor, while the rest ends up in healthy tissues due to target-mediated internalization and nonspecific uptake. The model suggests that the dual-positive tumor cell targeting specificity with bispecific antibodies is likely to be higher at lower drug concentrations and doses. However, this can be offset by elevated drug exposure in more accessible healthy tissues, primarily endothelium. The balance of exposure can be shifted toward tumor cells by using higher doses, albeit at the expense of more extensive target engagement elsewhere in the body, suggesting the need to adapt the toxicity of the payload if ADCs are considered. We suggest that PBPK modeling can guide and support biologics and bsmAb development, from target evaluation and drug optimization to therapeutic dose selection.","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"17 1","pages":"2492236"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and tolerability of intramuscular sotrovimab administered at different injection sites: results from the Phase 1 COSMIC study. 在不同注射部位肌注sotrovimab的安全性和耐受性：来自一期COSMIC研究的结果

IF 5.6 2区医学

mAbs Pub Date : 2025-12-01 Epub Date: 2025-01-29 DOI: 10.1080/19420862.2025.2456467

Jennifer Moore, Alicia Aylott, Wen-Hung Chen, Jerzy Daniluk, Ian A Hawes, Sergio Parra, Prosenjit Sarkar, Yasmin Sanchez-Pearson, Megan Turner, Amanda Peppercorn, Andrew Skingsley

引用次数: 0

An antibody developability triaging pipeline exploiting protein language models. 利用蛋白质语言模型的抗体可开发性分级管道。

IF 5.6 2区医学

mAbs Pub Date : 2025-12-01 Epub Date: 2025-03-04 DOI: 10.1080/19420862.2025.2472009

James Sweet-Jones, Andrew C R Martin

引用次数: 0

Process development for production of non-originator NISTmAb from CHO and NS0 cell lines. 从CHO和NS0细胞系生产非起始源NISTmAb的工艺开发。

IF 5.6 2区医学

mAbs Pub Date : 2025-12-01 Epub Date: 2025-05-22 DOI: 10.1080/19420862.2025.2505088

Erica J Fratz-Berilla, Nicole Azer, Xin Bush, JungHyun Kim, Casey Kohnhorst

{"title":"Process development for production of non-originator NISTmAb from CHO and NS0 cell lines.","authors":"Erica J Fratz-Berilla, Nicole Azer, Xin Bush, JungHyun Kim, Casey Kohnhorst","doi":"10.1080/19420862.2025.2505088","DOIUrl":"10.1080/19420862.2025.2505088","url":null,"abstract":"Cell lines that produce non-originator versions of the National Institute of Standards and Technology (NIST) monoclonal antibody reference material 8671 (NISTmAb) are invaluable to the biopharmaceutical industry because, unlike typical commercial cell lines, they can be used on a collaborative and noncompetitive basis for bioprocess development. NIST has generated NS0 clones, NISTCHO research-grade test material 10197 and reference material 8675 NISTCHO to fill this need. We set out to optimize seed train procedures, media and feeding strategies, and stirred tank and rocking bioreactor processes to facilitate our studies on the effects of cell substrate and bioreactor process parameters on non-originator NISTmAb quality attributes. For two NS0 clones and NISTCHO, we improved the baseline methods for seed train culture and demonstrated the critical roles of agitation and gassing strategies for stirred-tank bioreactor operations. For NISTCHO we also tested fed-batch and perfusion processes in rocking bioreactors, identifying several critical process parameters and in-process controls. In this work, for the NIST NS0-59 and NS0-66 clones, we demonstrated that shake flask geometry was critical for culturing a highly viable seed train with a high growth rate and exhibited impacts of feeds, agitation, and gassing during initial bioreactor process development. We identified agitation rates and gassing strategy as critical process parameters for NISTCHO stirred-tank bioreactor operations and established processes for fed-batch and perfusion rocking bioreactor operations. We anticipate this work to benefit the growing number of researchers employing non-originator NISTmAb-expressing cell lines to support precompetitive innovation in biomanufacturing.","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"17 1","pages":"2505088"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Data-driven analyses of human antibody variable domain germlines: pairings, sequences and structural features. 人抗体可变结构域种系的数据驱动分析：配对、序列和结构特征。

IF 5.6 2区医学

mAbs Pub Date : 2025-12-01 Epub Date: 2025-05-25 DOI: 10.1080/19420862.2025.2507950

Clarissa A Seidler, Vera A Spanke, Jakob Gamper, Alexander Bujotzek, Guy Georges, Klaus R Liedl

{"title":"Data-driven analyses of human antibody variable domain germlines: pairings, sequences and structural features.","authors":"Clarissa A Seidler, Vera A Spanke, Jakob Gamper, Alexander Bujotzek, Guy Georges, Klaus R Liedl","doi":"10.1080/19420862.2025.2507950","DOIUrl":"10.1080/19420862.2025.2507950","url":null,"abstract":"The Observed Antibody Space provides the most abundant collection of annotated paired antibody variable domain sequences, thus offering a unique platform for the systematic investigation of the factors governing the pairing of antibody heavy and light chains. By examining a range of characteristics, including amino acid conservation, structural features, charge distribution, and interface residue identity, we challenge the prevailing assumption that pairing is random. Our findings indicate that specific physicochemical properties of single amino acid residues may influence the compatibility and affinity of heavy and light chain combinations. Further structural analyses based on antibody Fv fragments deposited in the Protein Data Bank (PDB) provide insights into the underlying structural features driving these pairing preferences, including a novel definition for the residues constituting the VH-VL interface, based on a collection of over 3500 structures. These results have significant implications for understanding antibody assembly and may guide the rational design of therapeutic antibodies with desired properties. Moreover, we provide a complete description and reference characterizing the various human germlines.","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"17 1","pages":"2507950"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants. 将免疫文库探测与基于结构的计算设计相结合，开发针对新出现的SARS-CoV-2变体的有效中和纳米体。

IF 5.6 2区医学

mAbs Pub Date : 2025-12-01 Epub Date: 2025-05-06 DOI: 10.1080/19420862.2025.2499595

Lidia Cerdán, Katixa Silva, Daniel Rodríguez-Martín, Patricia Pérez, María A Noriega, Ana Esteban Martín, Alfonso Gutiérrez-Adán, Yago Margolles, Juan A Corbera, Miguel A Martín-Acebes, Juan García-Arriaza, Juan Fernández-Recio, Luis A Fernández, José M Casasnovas

{"title":"Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants.","authors":"Lidia Cerdán, Katixa Silva, Daniel Rodríguez-Martín, Patricia Pérez, María A Noriega, Ana Esteban Martín, Alfonso Gutiérrez-Adán, Yago Margolles, Juan A Corbera, Miguel A Martín-Acebes, Juan García-Arriaza, Juan Fernández-Recio, Luis A Fernández, José M Casasnovas","doi":"10.1080/19420862.2025.2499595","DOIUrl":"https://doi.org/10.1080/19420862.2025.2499595","url":null,"abstract":"To generate antibodies (Abs) against SARS-CoV-2 emerging variants, we integrated multiple tools and engineered molecules with excellent neutralizing breadth and potency. Initially, the screening of an immune library identified a nanobody (Nb), termed Nb4, specific to the receptor-binding domain (RBD) of the Omicron BA.1 variant. A Nb4-derived heavy chain antibody (hcAb4) recognized the spike (S) of the Wuhan, Beta, Delta, Omicron BA.1, and BA.5 SARS-CoV-2 variants. A high-resolution crystal structure of the Nb4 variable (VHH) domain in complex with the SARS-CoV-2 RBD (Wuhan) defined the Nb4 binding mode and interface. The Nb4 VHH domain grasped the RBD and covered most of its outer face, including the core and the receptor-binding motif (RBM), which was consistent with hcAb4 blocking RBD binding to the SARS-CoV-2 receptor. In mouse models, a humanized hcAb4 showed therapeutic potential and prevented the replication of SARS-CoV-2 BA.1 virus in the lungs of the animals. In vitro, hcAb4 neutralized Wuhan, Beta, Delta, Omicron BA.1, and BA.5 viral variants, as well as the BQ.1.1 subvariant, but showed poor neutralization against the Omicron XBB.1.5. Structure-based computation of the RBD-Nb4 interface identified three Nb4 residues with a reduced contribution to the interaction with the XBB.1.5 RBD. Site-saturation mutagenesis of these residues resulted in two hcAb4 mutants with enhanced XBB.1.5 S binding and virus neutralization, further improved by mutant Nb4 trimers. This research highlights an approach that combines library screening, Nb engineering, and structure-based computational predictions for the generation of SARS-CoV-2 Omicron-specific Abs and their adaptation to emerging variants.","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"17 1","pages":"2499595"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leveraging multi-modal feature learning for predictions of antibody viscosity. 利用多模态特征学习预测抗体黏度。

IF 5.6 2区医学

mAbs Pub Date : 2025-12-01 Epub Date: 2025-04-11 DOI: 10.1080/19420862.2025.2490788

Krishna D B Anapindi, Kai Liu, Willie Wang, Yao Yu, Yan He, Edward J Hsieh, Ying Huang, Daniela Tomazela

{"title":"Leveraging multi-modal feature learning for predictions of antibody viscosity.","authors":"Krishna D B Anapindi, Kai Liu, Willie Wang, Yao Yu, Yan He, Edward J Hsieh, Ying Huang, Daniela Tomazela","doi":"10.1080/19420862.2025.2490788","DOIUrl":"https://doi.org/10.1080/19420862.2025.2490788","url":null,"abstract":"The shift toward subcutaneous administration for biologic therapeutics has gained momentum due to its patient-friendly nature, convenience, reduced healthcare burden, and improved compliance compared to traditional intravenous infusions. However, a significant challenge associated with this transition is managing the viscosity of the administered solutions. High viscosity poses substantial development and manufacturability challenges, directly affecting patients by increasing injection time and causing pain at the injection site. Furthermore, high viscosity formulations can prolong residence time at the injection site, affecting absorption kinetics and potentially altering the intended pharmacological profile and therapeutic efficacy of the biologic candidate. Here, we report the application of a multimodal feature learning workflow for predicting the viscosity of antibodies in therapeutics discovery. It integrates multiple data sources including sequence, structural, physicochemical properties, as well as embeddings from a language model. This approach enables the model to learn from various underlying rules, such as physicochemical rules from molecular simulations and protein evolutionary patterns captured by large, pre-trained deep learning models. By comparing the effectiveness of this approach to other selected published viscosity prediction methods, this study provides insights into their intrinsic viscosity predictive potential and usability in early-stage therapeutics antibody development pipelines.","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"17 1","pages":"2490788"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis. AD-214是一种抗cxcr4 i-body-Fc融合治疗特发性肺纤维化的药物。

IF 5.6 2区医学

mAbs Pub Date : 2025-12-01 Epub Date: 2025-05-21 DOI: 10.1080/19420862.2025.2505090

Jason P Lynch, Louise Organ, Khamis Tomusange, Lukasz Kowalczyk, Dallas J Hartman, Angus Tester, Chris Hosking, Michael Foley

{"title":"Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis.","authors":"Jason P Lynch, Louise Organ, Khamis Tomusange, Lukasz Kowalczyk, Dallas J Hartman, Angus Tester, Chris Hosking, Michael Foley","doi":"10.1080/19420862.2025.2505090","DOIUrl":"10.1080/19420862.2025.2505090","url":null,"abstract":"Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by scarring and tissue remodeling. Current treatments have limited efficacy and significant side effects. To address these limitations, we developed AD-214, an anti-CXCR4-Fc-fusion protein composed of an anti-CXCR4 i-body (AD-114) tethered at its C terminus to constant domains 2 and 3 of the Fc region of a mutated human IgG1 lacking effector function. AD-214 binds with high affinity and specificity to CXCR4, modulates intracellular signaling, and inhibits key fibrotic pathways. Using fibrosis models, we demonstrate that AD-214 treatment significantly reduces collagen deposition and lung remodeling and has a unique mode of action. In Phase 1 clinical trials, intravenous infusion of AD-214 led to high and sustained CXCR4 receptor occupancy (RO), but whether RO and efficacy are causally linked remained to be determined. Herein, we demonstrate that CXCR4 RO by AD-214 inhibits primary human leukocyte migration, a model fibrotic process, and that migration inhibition is achievable at concentrations of AD-214 present in the serum of healthy human volunteers administered AD-214. Taken together, these data provide proof of concept for AD-214 as a novel treatment strategy for IPF and suggest that clinically feasible dosing regimens may be efficacious.","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"17 1","pages":"2505090"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

mAbs最新文献